

Conforms to Regulation (EC) No. 1907/2006 (REACH), Annex II, as amended by Commission Regulation (EU) 2020/878

# SAFETY DATA SHEET

F300-HT SEMI-GLOSS BASE ALUMINIUM

# SECTION 1: Identification of the substance/mixture and of the company/ undertaking

### 1.1 Product identifier

Product name SDS code : F300-HT SEMI-GLOSS BASE ALUMINIUM : 21300500B

### 1.2 Relevant identified uses of the substance or mixture and uses advised against

	Identified uses	
Paint. Professional use	e Industrial use	
	Uses advised against	
All other uses		
Product uso	Solvent here coating for interior and exterior use	

Product use

: Solvent borne coating for interior and exterior use.

### 1.3 Details of the supplier of the safety data sheet

MAPAERO SAS 10, Avenue de la Rijole CS30098 09103 PAMIERS Cedex France e-mail address of person : PSRA PAMIERS@akzonobel.com

responsible for this SDS

### 1.4 Emergency telephone number

National advisory body/Poison Center			
Telephone number	: 145		
<u>Supplier</u>			
Telephone number	: +33 (0)5 34 01 34 01		
	+33 (0)5 61 60 23 30		
Hours of operation	:		

# **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

Product definition : Mixture

### Classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Flam. Liq. 3, H226 Skin Irrit. 2, H315 Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H336 STOT RE 2, H373 Aquatic Chronic 3, H412

The product is classified as hazardous according to Regulation (EC) 1272/2008 as amended.

Date of issue/Date of revision	: 1-10-2022	Version : 1	
Date of previous issue	: No previous validation	1/19	AkzoNobel

# **SECTION 2: Hazards identification**

See Section 16 for the full text of the H statements declared above. See Section 11 for more detailed information on health effects and symptoms.

### 2.2 Label elements

Hazard pictograms	
Signal word	: Warning
Hazard statements	<ul> <li>Flammable liquid and vapor. Causes skin irritation. Causes serious eye irritation. May cause drowsiness or dizziness. Suspected of causing cancer. May cause damage to organs through prolonged or repeated exposure. Harmful to aquatic life with long lasting effects.</li> </ul>
Precautionary statements	
Prevention	: Obtain special instructions before use. Wear protective gloves, protective clothing and eye or face protection. Keep away from heat, hot surfaces, sparks, open flames and other ignition sources. No smoking. Avoid release to the environment. Do not breathe vapor. Wash hands thoroughly after handling.
Response	: IF exposed or concerned: Get medical advice or attention. IF INHALED: Call a POISON CENTER or doctor if you feel unwell. Take off contaminated clothing and wash it before reuse. IF ON SKIN: Wash with plenty of water. IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. If eye irritation persists: Get medical advice or attention.
Storage	: Store in a well-ventilated place. Keep container tightly closed. Keep cool.
Disposal	: Dispose of contents and container in accordance with all local, regional, national and international regulations.
Hazardous ingredients	<ul> <li>n-butyl acetate</li> <li>Reaction mass of ethylbenzene and xylene</li> <li>4-methylpentan-2-one</li> </ul>
Supplemental label elements	: Contains 4-morpholinecarbaldehyde. May produce an allergic reaction.
Annex XVII - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles	: Not applicable.
Special packaging requirem	<u>ients</u>
Containers to be fitted with child-resistant fastenings	: Not applicable.
Tactile warning of danger	: Not applicable.
2.3 Other hazards	
Product meets the criteria for PBT or vPvB according to Regulation (EC) No. 1907/2006, Annex XIII	: This mixture does not contain any substances that are assessed to be a PBT or a vPvB.



# **SECTION 2: Hazards identification**

Other hazards which do : None known. not result in classification

# **SECTION 3: Composition/information on ingredients**

3.2 Mixtures : M Product/ingredient name	lixture Identifiers	%	Regulation (EC) No.	Туре
			1272/2008 [CLP]	. , , , ,
n-butyl acetate	REACH #: 01-2119485493-29 EC: 204-658-1 CAS: 123-86-4 Index: 607-025-00-1	≥25 - ≤50	Flam. Liq. 3, H226 STOT SE 3, H336 EUH066	[1] [2]
Reaction mass of ethylbenzene and xylene	REACH #: 01-2119488216-32 EC: 905-588-0	≥10 - ≤15	Flam. Liq. 3, H226 Acute Tox. 4, H312 Acute Tox. 4, H332 Skin Irrit. 2, H315 Eye Irrit. 2, H319 STOT SE 3, H335 STOT RE 2, H373 Asp. Tox. 1, H304 Aquatic Chronic 3, H412	[1] [2]
4-methylpentan-2-one	EC: 203-550-1 CAS: 108-10-1 Index: 606-004-00-4	≤5	Flam. Liq. 2, H225 Acute Tox. 4, H332 Eye Irrit. 2, H319 Carc. 2, H351 STOT SE 3, H336 EUH066	[1] [2]
Naphtha (petroleum), hydrotreated heavy	REACH #: 01-2119486659-16 EC: 265-150-3 CAS: 64742-48-9 Index: 649-327-00-6	≤3	Flam. Liq. 3, H226 STOT SE 3, H336 Asp. Tox. 1, H304 EUH066	[1] [2]
Solvent naphtha (petroleum), light arom.	REACH #: 01-2119455851-35 EC: 265-199-0 CAS: 64742-95-6	≤2.5	Flam. Liq. 3, H226 STOT SE 3, H335 STOT SE 3, H336 Asp. Tox. 1, H304 Aquatic Chronic 2, H411 EUH066	[1]
butan-1-ol	REACH #: 01-2119484630-38 EC: 200-751-6 CAS: 71-36-3 Index: 603-004-00-6	≤1.5	Flam. Liq. 3, H226 Acute Tox. 4, H302 Skin Irrit. 2, H315 Eye Dam. 1, H318 STOT SE 3, H335 STOT SE 3, H336	[1] [2]
4-morpholinecarbaldehyde	EC: 224-518-3 CAS: 4394-85-8	≤0.3	Skin Sens. 1, H317 See Section 16 for the full text of the H statements declared above.	[1]

There are no additional ingredients present which, within the current knowledge of the supplier and in the concentrations applicable, are classified as hazardous to health or the environment, are PBTs, vPvBs or Substances of equivalent concern, or have been assigned a workplace exposure limit and hence require reporting in this section. <u>Type</u>



## **SECTION 3: Composition/information on ingredients**

[1] Substance classified with a health or environmental hazard

[2] Substance with a workplace exposure limit

[3] Substance meets the criteria for PBT according to Regulation (EC) No. 1907/2006, Annex XIII

[4] Substance meets the criteria for vPvB according to Regulation (EC) No. 1907/2006, Annex XIII

[5] Substance of equivalent concern

[6] Additional disclosure due to company policy

Occupational exposure limits, if available, are listed in Section 8.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures Eye contact : Immediately flush eyes with plenty of water, occasionally lifting the upper and lower eyelids. Check for and remove any contact lenses. Continue to rinse for at least 10 minutes. Get medical attention. Inhalation : Remove victim to fresh air and keep at rest in a position comfortable for breathing. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. If not breathing, if breathing is irregular or if respiratory arrest occurs, provide artificial respiration or oxygen by trained personnel. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation. Get medical attention. If necessary, call a poison center or physician. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. : Flush contaminated skin with plenty of water. Remove contaminated clothing and Skin contact shoes. Continue to rinse for at least 10 minutes. Get medical attention. Wash clothing before reuse. Clean shoes thoroughly before reuse. : Wash out mouth with water. Remove dentures if any. Remove victim to fresh air Ingestion and keep at rest in a position comfortable for breathing. If material has been swallowed and the exposed person is conscious, give small quantities of water to drink. Stop if the exposed person feels sick as vomiting may be dangerous. Do not induce vomiting unless directed to do so by medical personnel. If vomiting occurs, the head should be kept low so that vomit does not enter the lungs. Get medical attention. If necessary, call a poison center or physician. Never give anything by mouth to an unconscious person. If unconscious, place in recovery position and get medical attention immediately. Maintain an open airway. Loosen tight clothing such as a collar, tie, belt or waistband. Protection of first-aiders : No action shall be taken involving any personal risk or without suitable training. If it is suspected that fumes are still present, the rescuer should wear an appropriate mask or self-contained breathing apparatus. It may be dangerous to the person providing aid to give mouth-to-mouth resuscitation.

### 4.2 Most important symptoms and effects, both acute and delayed

There are no data available on the mixture itself. The mixture has been assessed following the conventional method of the CLP Regulation (EC) No 1272/2008 and is classified for toxicological properties accordingly. See Sections 2 and 3 for details.

Exposure to component solvent vapor concentrations in excess of the stated occupational exposure limit may result in adverse health effects such as mucous membrane and respiratory system irritation and adverse effects on the kidneys, liver and central nervous system. Symptoms and signs include headache, dizziness, fatigue, muscular weakness, drowsiness and, in extreme cases, loss of consciousness.

Solvents may cause some of the above effects by absorption through the skin. Repeated or prolonged contact with the mixture may cause removal of natural fat from the skin, resulting in non-allergic contact dermatitis and absorption through the skin.

If splashed in the eyes, the liquid may cause irritation and reversible damage.

Ingestion may cause nausea, diarrhea and vomiting.

This takes into account, where known, delayed and immediate effects and also chronic effects of components from short-term and long-term exposure by oral, inhalation and dermal routes of exposure and eye contact.

Contains 4-morpholinecarbaldehyde. May produce an allergic reaction.

Date of issue/Date of revision	: 1-10-2022	Version : 1	
Date of previous issue	: No previous validation	4/19	AkzoNobe

# **SECTION 4: First aid measures**

Over-exposure signs/sympt	Over-exposure signs/symptoms			
Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness			
Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness			
Skin contact	: Adverse symptoms may include the following: irritation redness			
Ingestion	: No specific data.			

### 4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician	<ul> <li>Treat symptomatically. Contact poison treatment specialist immediately if large quantities have been ingested or inhaled.</li> </ul>
Specific treatments	: No specific treatment.

# **SECTION 5: Firefighting measures**

5.1 Extinguishing media		
Suitable extinguishing media	se dry chemical, CO <sub>2</sub> , water spray (fog) or foam.	
Unsuitable extinguishing media	o not use water jet.	
5.2 Special hazards arising f	he substance or mixture	
Hazards from the substance or mixture	lammable liquid and vapor. Runoff to sewer may create fire or explosion h a fire or if heated, a pressure increase will occur and the container may be ne risk of a subsequent explosion. This material is harmful to aquatic life w asting effects. Fire water contaminated with this material must be contained revented from being discharged to any waterway, sewer or drain.	urst, with ⁄ith long
Hazardous combustion products	ecomposition products may include the following materials: arbon dioxide arbon monoxide netal oxide/oxides	
5.3 Advice for firefighters		
Special protective actions for fire-fighters	romptly isolate the scene by removing all persons from the vicinity of the in here is a fire. No action shall be taken involving any personal risk or withou uitable training. Move containers from fire area if this can be done without lse water spray to keep fire-exposed containers cool.	ıt
Special protective equipment for fire-fighters	ire-fighters should wear appropriate protective equipment and self-container reathing apparatus (SCBA) with a full face-piece operated in positive press node. Clothing for fire-fighters (including helmets, protective boots and glov onforming to European standard EN 469 will provide a basic level of protect hemical incidents.	sure ves)



### **SECTION 6: Accidental release measures**

### 6.1 Personal precautions, protective equipment and emergency procedures

• •	
For non-emergency personnel	: No action shall be taken involving any personal risk or without suitable training. Evacuate surrounding areas. Keep unnecessary and unprotected personnel from entering. Do not touch or walk through spilled material. Shut off all ignition sources. No flares, smoking or flames in hazard area. Avoid breathing vapor or mist. Provide adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Put on appropriate personal protective equipment.
For emergency responders	: If specialized clothing is required to deal with the spillage, take note of any information in Section 8 on suitable and unsuitable materials. See also the information in "For non-emergency personnel".
6.2 Environmental precautions	: Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers. Inform the relevant authorities if the product has caused environmental pollution (sewers, waterways, soil or air). Water polluting material. May be harmful to the environment if released in large quantities.
6.3 Methods and materials for	containment and cleaning up
Small spill	: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Dilute with water and mop up if water-soluble. Alternatively, or if water-insoluble, absorb with an inert dry material and place in an appropriate waste disposal container. Dispose of via a licensed waste disposal contractor.
Large spill	: Stop leak if without risk. Move containers from spill area. Use spark-proof tools and explosion-proof equipment. Approach release from upwind. Prevent entry into sewers, water courses, basements or confined areas. Wash spillages into an effluent treatment plant or proceed as follows. Contain and collect spillage with pop-

effluent treatment plant or proceed as follows. Contain and collect spillage with noncombustible, absorbent material e.g. sand, earth, vermiculite or diatomaceous earth and place in container for disposal according to local regulations. Dispose of via a licensed waste disposal contractor. Contaminated absorbent material may pose the same hazard as the spilled product.

# 6.4 Reference to other<br/>sections: See Section 1 for emergency contact information.<br/>See Section 8 for information on appropriate personal protective equipment.<br/>See Section 13 for additional waste treatment information.

### **SECTION 7: Handling and storage**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 7.1 Precautions for safe handling

Protective measures	obtain special instructions be have been read and underste breathe vapor or mist. Do no with adequate ventilation. W inadequate. Do not enter sto ventilated. Keep in the origin compatible material, kept tigh heat, sparks, open flame or a (ventilating, lighting and mate Take precautionary measure	Put on appropriate personal protective equipment (see Section 8). Avoid exposure - obtain special instructions before use. Do not handle until all safety precautions have been read and understood. Do not get in eyes or on skin or clothing. Do not breathe vapor or mist. Do not ingest. Avoid release to the environment. Use only with adequate ventilation. Wear appropriate respirator when ventilation is inadequate. Do not enter storage areas and confined spaces unless adequately ventilated. Keep in the original container or an approved alternative made from a compatible material, kept tightly closed when not in use. Store and use away from heat, sparks, open flame or any other ignition source. Use explosion-proof electrical (ventilating, lighting and material handling) equipment. Use only non-sparking tools. Take precautionary measures against electrostatic discharges. Empty containers retain product residue and can be hazardous. Do not reuse container.	
Advice on general occupational hygiene	: Eating, drinking and smoking should be prohibited in areas where this material is handled, stored and processed. Workers should wash hands and face before eating, drinking and smoking. Remove contaminated clothing and protective equipment before entering eating areas. See also Section 8 for additional information on hygiene measures.		
Date of issue/Date of revision	: 1-10-2022	Version : 1	
Date of previous issue	: No previous validation	6/19	AkzoNobel

## **SECTION 7: Handling and storage**

### 7.2 Conditions for safe storage, including any incompatibilities

Store in accordance with local regulations. Store in a segregated and approved area. Store in original container protected from direct sunlight in a dry, cool and well-ventilated area, away from incompatible materials (see Section 10) and food and drink. Store locked up. Eliminate all ignition sources. Separate from oxidizing materials. Keep container tightly closed and sealed until ready for use. Containers that have been opened must be carefully resealed and kept upright to prevent leakage. Do not store in unlabeled containers. Use appropriate containment to avoid environmental contamination. See Section 10 for incompatible materials before handling or use.

### Seveso Directive - Reporting thresholds

### Danger criteria

Ca		Notification and MAPP threshold	Safety report threshold
P	5c	5000 tonne	50000 tonne

### 7.3 Specific end use(s)

Recommendations	:	Not available.
Industrial sector specific	:	Not available.

Industrial sector specific solutions

### **SECTION 8: Exposure controls/personal protection**

The information in this section contains generic advice and guidance. Information is provided based on typical anticipated uses of the product. Additional measures might be required for bulk handling or other uses that could significantly increase worker exposure or environmental releases.

### 8.1 Control parameters

### **Occupational exposure limits**

Product/ingredient name	Exposure limit values
n-butyl acetate	SUVA (Switzerland, 1/2020). Notes: not temporary
	STEL: 960 mg/m <sup>3</sup> 15 minutes.
	STEL: 200 ppm 15 minutes.
	TWA: 480 mg/m <sup>3</sup> 8 hours.
	TWA: 100 ppm 8 hours.
Reaction mass of ethylbenzene and xylene	SUVA (Switzerland, 1/2020). Absorbed through skin. Notes:
	not temporary
	STEL: 870 mg/m <sup>3</sup> 15 minutes.
	STEL: 200 ppm 15 minutes.
	TWA: 435 mg/m <sup>3</sup> 8 hours.
	TWA: 100 ppm 8 hours.
4-methylpentan-2-one	SUVA (Switzerland, 1/2020). Absorbed through skin. Notes:
	not temporary
	STEL: 164 mg/m <sup>3</sup> 15 minutes.
	STEL: 40 ppm 15 minutes.
	TWA: 82 mg/m <sup>3</sup> 8 hours.
	TWA: 20 ppm 8 hours.
Naphtha (petroleum), hydrotreated heavy	SUVA (Switzerland, 1/2020).
	STEL: 600 mg/m <sup>3</sup> 15 minutes.
	STEL: 100 ppm 15 minutes.
	TWA: 50 ppm 8 hours.
	TWA: 300 mg/m <sup>3</sup> 8 hours.
butan-1-ol	SUVA (Switzerland, 1/2020). Notes: not temporary
	STEL: 310 mg/m <sup>3</sup> 15 minutes.
	STEL: 100 ppm 15 minutes.
	TWA: 310 mg/m <sup>3</sup> 8 hours.
	TWA: 100 ppm 8 hours.



# **SECTION 8: Exposure controls/personal protection**

**Recommended monitoring procedures**If this product contains ingredients with exposure limits, personal, workplace atmosphere or biological monitoring may be required to determine the effectiveness of the ventilation or other control measures and/or the necessity to use respiratory protective equipment. Reference should be made to monitoring standards, such as the following: European Standard EN 689 (Workplace atmospheres - Guidance for the assessment of exposure by inhalation to chemical agents for comparison with limit values and measurement strategy) European Standard EN 14042 (Workplace atmospheres - Guide for the application and use of procedures for the assessment of exposure to chemical and biological agents) European Standard EN 482 (Workplace atmospheres - General requirements for the performance of procedures for the measurement of chemical agents) Reference to national guidance documents for methods for the determination of hazardous substances will also be required.

### **DNELs/DMELs**

Amethylpentan-2-oneDNELLong term Dermal Long term Dermal3.4 mg/kg Syst bw/daypopulation General populationSyst Syst WorkersDNELLong term Dermal12 mg/m3 Unstation InhalationGeneral populationSyst youlationDNELLong term Inhalation12 mg/m3 UnstationGeneral populationSyst youlationDNELLong term Inhalation102.34 mg/ m3General populationLocz tormal populationDNELLong term Inhalation102.34 mg/ m3General populationLocz tormal populationDNELShort term Inhalation859.7 mg/ general populationGeneral populationLocz tormal populationDNELShort term Inhalation859.7 mg/ general populationGeneral populationLocz tormal populationDNELShort term Inhalation960 mg/m3 WorkersWorkersLocz tormal populationDNELShort term Inhalation16 mg/kg bw/day WorkersGeneral populationSyst populationDNELLong term Oral Inhalation1.6 mg/kg bw/day WorkersGeneral populationSyst populationA+methylpentan-2-oneDNELShort term Inhalation108 mg/kg Bord term Dermal InhalationGeneral populationSyst population4-methylpentan-2-oneDNELLong term Dermal Inhalation18 mg/kg Bord general populationGeneral populationSyst population4-methylpentan-2-one <th>Effects</th> <th>Population</th> <th>Value</th> <th>Exposure</th> <th>Туре</th> <th>Product/ingredient name</th>	Effects	Population	Value	Exposure	Туре	Product/ingredient name
DNEL bmillLong term Dermal bmill3.4 mg/kg population bm/dayGeneral populationSyst populationDNEL bmillLong term inhalation12 mg/m³ populationGeneral populationSyst populationDNEL bmillLong term inhalation48 mg/m³ m³General populationSyst populationDNEL bmillLong term inhalation102.34 mg/ m³ populationGeneral populationLoca populationDNEL bmillLong term inhalation480 mg/m³ m³ populationGeneral populationLoca populationDNEL bmillLong term inhalation859.7 mg/ general populationGeneral populationLoca populationDNEL bmillShort term inhalation960 mg/m³ m³ populationWorkersLoca populationDNEL bmillShort term inhalation960 mg/m³ m³ populationWorkersSyst populationDNEL bmillLong term Oral inhalation1.6 mg/kg general populationGeneral syst populationSyst populationDNEL bmillLong term Dermal inhalation108 mg/kg bw/dayWorkersSyst populationDNEL bmillLong term Dermal inhalation108 mg/kg general populationWorkersSyst populationA-methylpentan-2-oneDNEL bmillLong term Dermal inhalation108 mg/kg general general bw/dayGeneral syst populationSyst population4-methylpentan-2-oneDNEL bmill <td>Systemic</td> <td></td> <td></td> <td>Long term Oral</td> <td>DNEL</td> <td>n-butyl acetate</td>	Systemic			Long term Oral	DNEL	n-butyl acetate
bw/daypopulationDNELLong term Dermalbw/daypopulationDNELLong term12 mg/m³GeneralInhalationDNELLong term48 mg/m³WorkersDNELLong term102.34 mg/GeneralInhalationm³populationDNELLong term102.34 mg/Inhalationm³populationDNELShort term859.7 mg/Inhalationm³DNELShort term859.7 mg/Inhalationm³DNELShort term859.7 mg/Inhalationm³DNELShort termInhalationm³DNELShort termShort term960 mg/m³WorkersLocaInhalationm³DNELShort termInhalation1.6 mg/kgDNELCong term OralInhalation1.6 mg/kgDNELLong termInhalation1.8 mg/m³QualitonDNELLong term Dermal108 mg/kgbw/dayDNELDNELLong term Dermalbw/dayWorkersDNELShort termDNELShort termInhalation108 mg/kgpopulationpopulationDNELLong term Dermalbw/dayWorkersDNELShort termInhalation289 mg/m³UNELLong term OralInhalation4.2 mg/kgDNELLong term Oral </td <td></td> <td>population</td> <td></td> <td></td> <td></td> <td></td>		population				
bw/daypopulationDNELLong term Dermalbw/daypopulationDNELLong term12 mg/m³GeneralInhalationDNELLong term48 mg/m³WorkersDNELLong term102.34 mg/GeneralInhalationm³populationDNELLong term102.34 mg/Inhalationm³populationDNELShort term859.7 mg/Inhalationm³DNELShort term859.7 mg/Inhalationm³DNELShort term859.7 mg/Inhalationm³DNELShort termInhalationm³DNELShort termShort term960 mg/m³WorkersLocaInhalationm³DNELShort termInhalation1.6 mg/kgDNELCong term OralInhalation1.6 mg/kgDNELLong termInhalation1.8 mg/m³QualitonDNELLong term Dermal108 mg/kgbw/dayDNELDNELLong term Dermalbw/dayWorkersDNELShort termDNELShort termInhalation108 mg/kgpopulationpopulationDNELLong term Dermalbw/dayWorkersDNELShort termInhalation289 mg/m³UNELLong term OralInhalation4.2 mg/kgDNELLong term Oral </td <td>systemic</td> <td>General</td> <td>3.4 mg/kg</td> <td>Long term Dermal</td> <td>DNEL</td> <td></td>	systemic	General	3.4 mg/kg	Long term Dermal	DNEL	
A-methylpentan-2-oneDDD		population	bw/day			
DNEL InhalationLong term Inhalation12 mg/m³ opulationGeneral populationSystDNEL InhalationDNEL InhalationLong term Inhalation48 mg/m³WorkersSystDNEL InhalationDNEL InhalationLong term m³480 mg/m³General populationLoca termDNEL InhalationDNEL InhalationLong term m³480 mg/m³General populationLoca termDNEL InhalationShort term m³859.7 mg/ General populationGeneral populationLoca termDNEL InhalationShort term m³960 mg/m³WorkersLoca populationDNEL InhalationShort term population960 mg/m³WorkersLoca termDNEL InhalationDNEL InhalationLong term bw/day1.4.8 mg/m³General populationSyst populationDNEL Long term InhalationDNEL InhalationInfo mg/kg bw/dayGeneral populationSyst populationDNEL InhalationLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSyst populationDNEL InhalationLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSyst population4-methylpentan-2-oneDNEL InhalationLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSyst population4-methylpentan-2-oneDNEL InhalationLong term Dermal Inhalation1.8 mg/kg bw/dayGeneral pop	systemic	Workers	7 mg/kg	Long term Dermal	DNEL	
InhalationpopulationDNELLong term48 mg/m³WorkersSystInhalationInhalation102.34 mg/ populationGeneral populationLoca populationDNELLong term102.34 mg/ m³General populationLoca populationDNELLong term480 mg/m³WorkersLoca inhalationDNELShort term859.7 mg/ inhalationGeneral populationLoca inhalationDNELShort term859.7 mg/ inhalationGeneral populationLoca inhalationDNELShort term859.7 mg/ inhalationGeneral populationSyst populationDNELShort term960 mg/m³WorkersLoca inhalationDNELShort term960 mg/m³WorkersSyst populationDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSyst populationUNELLong term Dermal108 mg/kg bw/dayWorkersSyst population4-methylpentan-2-oneDNELLong term Dermal inhalation289 mg/m³ bw/dayWorkersSyst population4-methylpentan-2-oneDNELLong term Dermal inhalation4.2 mg/kg bw/dayGeneral populationSyst population0NELLong term Dermal inhalation1.8 mg			bw/day			
DNEL InhalationLong term Inhalation48 mg/m³WorkersSystDNEL InhalationDNEL InhalationLong term m³102.34 mg/ populationGeneral populationLoca populationDNEL InhalationDNEL InhalationShort term asso.859.7 mg/ populationGeneral populationLoca populationDNEL Short term InhalationShort term asso.960 mg/m³WorkersLoca populationDNEL Short term InhalationDNEL Short termShort term 960 mg/m³General populationSyst populationDNEL Short term InhalationDNEL InhalationShort term 960 mg/m³General populationSyst populationDNEL InhalationDNEL InhalationLong term Oral Inhalation1.6 mg/kg General populationGeneral Syst populationSyst populationDNEL InhalationDNEL InhalationLong term Oral Inhalation1.6 mg/kg General Syst populationGeneral Syst populationSyst populationDNEL InhalationDNEL InhalationLong term Dermal Inhalation108 mg/kg WorkersGeneral Syst populationSyst population4-methylpentan-2-oneDNEL DNEL Iong term Dermal InhalationLong term Dermal 4.2 mg/kg bw/dayGeneral Syst populationSyst population4-methylpentan-2-oneDNEL DNEL Iong term Dermal InhalationLong term Dermal 4.2 mg/kg bw/dayGeneral Syst populationSyst population <td>systemic</td> <td>General</td> <td>12 mg/m<sup>3</sup></td> <td>Long term</td> <td>DNEL</td> <td></td>	systemic	General	12 mg/m <sup>3</sup>	Long term	DNEL	
Inhalation DNELDNEL Long term102.34 mg/ populationGeneral populationLoca populationDNELLong term Inhalation480 mg/m³WorkersLoca populationDNELShort term Inhalation859.7 mg/ m³General populationLoca populationDNELShort term Inhalation960 mg/m³WorkersLoca generalDNELShort term Inhalation960 mg/m³WorkersSyst populationDNELShort term Inhalation960 mg/m³WorkersSyst populationDNELShort term Inhalation960 mg/m³WorkersSystDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSyst populationDNELLong term Inhalation108 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal Inhalation108 mg/kg bw/dayWorkersSyst populationDNELLong term Dermal Inhalation108 mg/kg bw/dayWorkersSyst population4-methylpentan-2-oneDNELLong term Dermal Inhalation4.2 mg/kg populationGeneral populationSyst population4-methylpentan-2-oneDNELLong term Dermal Inhalation4.2 mg/kg populationGeneral populationSyst population0NELLong term Dermal Inhalation1.8 mg/ populationGeneral popu	•		°,			
Inhalation DNEL Long term102.34 mg/ aboutationGeneral populationLoca topulationDNEL Inhalation InhalationDNEL InhalationLoca m³General populationLoca topulationDNEL Inhalation InhalationShort term B59.7 mg/ InhalationB59.7 mg/ General populationGeneral populationLoca topulationDNEL Short term InhalationShort term B60 mg/m³General populationSyst populationDNEL Short termShort term Inhalation960 mg/m³ WorkersWorkersSyst populationDNEL Short term InhalationDNEL Long term Oral1.6 mg/kg bw/dayGeneral populationSyst populationDNEL Long term Dermal InhalationDNEL Long term Dermal108 mg/kg bw/dayGeneral populationSyst populationDNEL Long term Dermal InhalationDNEL Long term Dermal108 mg/kg bw/dayGeneral populationSyst populationA-methylpentan-2-oneDNEL DNEL Long term DermalLong term Oral thalation1.6 mg/kg bw/dayGeneral populationSyst population4-methylpentan-2-oneDNEL DNEL Long term Dermal4.2 mg/kg bw/dayGeneral populationSyst population4-methylpentan-2-oneDNEL DNEL Long term Dermal4.2 mg/kg bw/dayGeneral populationSyst population0NEL DNEL Long term Dermal11.8 mg/ kg bw/dayWorkersSyst population0NEL DNEL DNEL DNEL	Systemic		48 mg/m <sup>3</sup>	Long term	DNEL	
Inhalationm³populationDNELLong term480 mg/m³WorkersLocaInhalationInhalation111DNELShort term859.7 mg/GeneralLocaInhalationm³populationSystInhalationm³populationSystInhalationm³WorkersLocaInhalationm³populationSystInhalationDNELShort term960 mg/m³WorkersLocaInhalationDNELShort term960 mg/m³WorkersSystInhalationDNELLong term Oral1.6 mg/kgGeneralSystInhalationDNELLong term14.8 mg/m³GeneralSystInhalationDNELLong term Dermal108 mg/kgGeneralSystInhalationDNELLong term Dermal108 mg/kgWorkersSystInhalationDNELLong term Dermal108 mg/kgWorkersSystInhalationDNELShort term289 mg/m³WorkersLocaInhalationDNELShort term289 mg/m³WorkersSystInhalationDNELLong term Oral4.2 mg/kgGeneralSystInhalationDNELLong term Dermal11.8 mg/GeneralSystInhalationDNELLong term Dermal11.8 mg/GeneralSystInhalationDNELLong term Dermal11.8 mg/kgGeneralSystInhal			Ũ			
Inhalationm³ Long termpopulationDNELLong term480 mg/m³UnderstandNettermNettermShort termNettermShort termNetterm<	ocal	General	102.34 ma/	Long term	DNEL	
DNELLong term Inhalation480 mg/m³WorkersLocaDNELShort term Inhalation859.7 mg/ m³General populationLocaDNELShort term Inhalation859.7 mg/ m³General populationSyst populationDNELShort term Inhalation960 mg/m³ WorkersWorkersLocaDNELShort term Inhalation960 mg/m³ WorkersWorkersLocaDNELShort term Inhalation960 mg/m³ WorkersWorkersSyst populationDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSyst populationDNELLong term Oral Inhalation1.6 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal Inhalation180 mg/kg bw/dayGeneral populationSyst population4-methylpentan-2-oneDNELLong term Dermal Inhalation180 mg/kg bw/dayWorkersSyst population4-methylpentan-2-oneDNELLong term Dermal Inhalation4.2 mg/kg populationGeneral Syst populationSyst population0NELLong term Dermal Inhalation11.8 mg/ kg bw/dayWorkersSyst population0NELLong term Dermal Inhalation11.8 mg/ kg bw/daySyst populationSyst population						
InhalationInhalationGeneral populationLoca populationDNELShort term859.7 mg/ InhalationGeneral populationSyst populationDNELShort term960 mg/m³WorkersLoca populationDNELShort term960 mg/m³WorkersLoca populationDNELShort term960 mg/m³WorkersLoca populationDNELShort term960 mg/m³WorkersSyst populationDNELShort term960 mg/m³WorkersSyst populationDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSyst populationDNELLong term11.8 mg/m³General populationSyst populationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSyst populationA-methylpentan-2-oneDNELLong term Dermal108 mg/kg bw/dayGeneral populationSyst population4-methylpentan-2-oneDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSyst population4-methylpentan-2-oneDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSyst populationDNELLong term Dermal11.8 mg/ kg bw/dayGeneral populationSyst populationDNELLong term Dermal11.8 mg/ kg bw/dayGeneral populationSyst populationDNEL	ocal				DNEL	
DNELShort term Inhalation859.7 mg/ m³General populationLoca systDNELShort term InhalationBNELShort term Inhalation960 mg/m³WorkersLoca populationDNELShort term Inhalation960 mg/m³WorkersLoca populationLoca populationLoca populationReaction mass of ethylbenzene and xyleneDNELShort term Inhalation960 mg/m³WorkersSyst populationDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSyst populationDNELLong term Oral1.4 8 mg/m³General populationSyst populationDNELLong term Inhalation108 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal Inhalation108 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal Inhalation108 mg/kg bw/dayWorkersSyst populationA-methylpentan-2-oneDNELLong term Oral Inhalation289 mg/m³ bw/dayWorkersSyst population4-methylpentan-2-oneDNELLong term Dermal Inhalation289 mg/m³ bw/dayWorkersSyst populationDNELLong term Dermal Inhalation11.8 mg/ bw/dayGeneral populationSyst populationDNELLong term Dermal Inhalation11.8 mg/ bw/dayGeneral populationSyst populationDNELLong term Dermal Inhalation11.8 mg/ bw/day						
Inhalationm³ SpopulationpopulationDNELShort term859.7 mg/ InhalationGeneral populationDNELShort term960 mg/m³WorkersLocaInhalationDNELShort term960 mg/m³WorkersSystInhalationDNELShort term960 mg/m³WorkersSystInhalationDNELLong term Oral1.6 mg/kgGeneral populationSystInhalationDNELLong term Oral1.6 mg/kgGeneral populationSystDNELLong term14.8 mg/m³General populationSystDNELLong term17 mg/m³WorkersSystInhalationDNELLong term Dermal108 mg/kgGeneral populationSystDNELLong term Dermal108 mg/kgGeneral populationSystDNELLong term Dermal180 mg/kgWorkersSystDNELShort term Inhalation289 mg/m³WorkersSystDNELShort term Inhalation289 mg/m³WorkersSystDNELLong term Oral4.2 mg/kgGeneral populationSystDNELLong term Dermal11.8 mg/ kg bw/daySystDNELLong term Dermal11.8 mg/ kg bw/daySystDNELLong term Dermal14.7 mg/m³General populationSystDNELLong term Dermal14.7 mg/m³General populationSystDNELLong term Dermal14.7 mg/m³Gener	ocal	General	859.7 ma/		DNEL	
A-methylpentan-2-oneDNELShort term inhalation DNELShort term inhalation inhalation DNELShort term inhalation polume859.7 mg/ population 960 mg/m³General population WorkersSyst Loca4-methylpentan-2-oneDNELShort term inhalation DNEL960 mg/m³WorkersSyst population general population DNELLong term Oral inhalation DNEL1.6 mg/kg population general population general population DNELGeneral population general population DNELSyst population general population DNELSyst population general population DNELSyst population population deneral populationSyst population general population deneral populationSyst syst population deneral population deneral populationSyst syst population deneral populationSyst syst population deneral population deneral populationSyst syst population deneral population deneral populationSyst syst syst population deneral populationSyst syst syst population deneral populationSyst syst syst syst deneral deneral populationSyst syst syst syst syst deneral populationSyst syst syst syst syst deneral populationSyst syst syst syst syst syst syst syst deneral populationSyst syst <b< td=""><td></td><td></td><td>-</td><td></td><td></td><td></td></b<>			-			
Inhalationm³ 960 mg/m³populationNREaction mass of ethylbenzene and xyleneDNELShort term Inhalation960 mg/m³WorkersLocaDNELShort term Inhalation960 mg/m³WorkersSystDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSystDNELLong term Inhalation14.8 mg/m³General populationSystDNELLong term Inhalation77 mg/m³WorkersSystDNELLong term Inhalation77 mg/m³WorkersSystDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystDNELShort term Inhalation289 mg/m³WorkersSystDNELShort term Inhalation289 mg/m³WorkersSystDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystDNELLong term Dermal11.8 mg/ kg bw/dayGeneral populationSystDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSystDNELLong term Dermal11.8 mg/ kg bw/dayGeneral populationSystDNELLong term Dermal11.7 mg/m³General populationSystDNELLong term Dermal11.7 mg/m³General populationSystDNELLong term Dermal11.7 mg/m³General populationSystDNELLo	systemic				DNEI	
A-methylpentan-2-oneDNELShort term inhalation960 mg/m³WorkersLocation4-methylpentan-2-oneDNELShort term inhalation960 mg/m³WorkersSyst population4-methylpentan-2-oneDNELLong term Dermal inhalation1.6 mg/kg bw/dayGeneral populationSyst population4-methylpentan-2-oneDNELLong term Dermal inhalation108 mg/kg bw/dayGeneral populationSyst population4-methylpentan-2-oneDNELLong term Dermal inhalation108 mg/kg bw/dayGeneral populationSyst population4-methylpentan-2-oneDNELLong term Dermal inhalation1.8 mg/kg bw/dayGeneral populationSyst population4-methylpentan-2-oneDNELLong term Dermal inhalation1.8 mg/kg bw/dayGeneral populationSyst population0NELLong term Dermal inhalation1.8 mg/kg bw/dayGeneral populationSyst population0NELLong term Dermal inhalation4.2 mg/kg bw/dayGeneral populationSyst population0NELLong term Dermal inhalation1.8 mg/ kg bw/dayWorkersSyst population0NELLong term Dermal inhalation1.8 mg/ kg bw/dayGeneral populationSyst population0NELLong term Dermal inhalation11.8 mg/ kg bw/dayGeneral populationSyst population0NELLong term Dermal inhalation14.7 mg/m³General populationSyst p	ysternio				DIVEL	
Reaction mass of ethylbenzene and xyleneDNELInhalation Short term Inhalation960 mg/m³ 960 mg/m³WorkersSyst syst populationDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSyst populationDNELLong term Inhalation14.8 mg/m³General populationSyst populationDNELLong term Inhalation77 mg/m³WorkersSyst populationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSyst populationA-methylpentan-2-oneDNELShort term Inhalation289 mg/m³ bw/dayWorkersSyst population4-methylpentan-2-oneDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSyst populationDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSyst populationDNELLong term Dermal14.7 mg/m³General gopulationSyst populationDNELLong term Dermal14.7 mg/m³General populationSyst populationDNELLong term Dermal14.7 mg/m³General populationSyst populationDNELLong term Dermal14.7 mg/m³General populationSyst <br< td=""><td>ocal</td><td></td><td></td><td></td><td></td><td></td></br<>	ocal					
Reaction mass of ethylbenzene and xyleneDNELShort term inhalation960 mg/m³WorkersSystDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSystDNELLong term inhalation14.8 mg/m³General populationSystDNELLong term inhalation14.8 mg/m³General populationSystDNELLong term inhalation77 mg/m³WorkersSystDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystDNELLong term Dermal180 mg/kg bw/dayGeneral populationSystDNELLong term Dermal180 mg/kg bw/dayWorkersSystDNELShort term inhalation289 mg/m³WorkersSystDNELShort term inhalation289 mg/m³WorkersSystDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystDNELLong term Dermal11.8 mg/ kg bw/dayGeneral populationSystDNELLong term Dermal14.7 mg/m³General gopulationSystDNELLong term Dermal14.7 mg/m³General gopulatio	ocar	WOIKEI3	300 mg/m		DINCL	
Reaction mass of ethylbenzene and xyleneInhalation Long term Oral1.6 mg/kg bw/dayGeneral populationSyst populationDNELLong term Inhalation DNELLong term Inhalation DNEL14.8 mg/m³General populationSyst populationDNELLong term Inhalation DNELTr mg/m³WorkersSyst populationDNELLong term Inhalation DNEL108 mg/kg bw/day UNELGeneral population WorkersSyst populationDNELLong term Dermal Inhalation DNEL108 mg/kg bw/day UNELGeneral populationSyst population4-methylpentan-2-oneDNELShort term Inhalation DNEL289 mg/m³ bw/day UNELWorkersSyst population4-methylpentan-2-oneDNELLong term Dermal Inhalation DNEL4.2 mg/kg bw/day UNELGeneral population UNELSyst bw/day UNELDNELLong term Dermal Inhalation11.8 mg/ kg bw/day UNELWorkersSyst populationDNELLong term Dermal Inhalation11.8 mg/ kg bw/day UNELWorkersSyst populationDNELLong term Dermal Inhalation11.8 mg/ kg bw/day UNELWorkersSyst populationDNELLong term Dermal Inhalation11.7 mg/m³General General populationSyst populationDNELLong term Dermal Inhalation11.7 mg/m³General populationSyst population	vetomio	Workore	$060 \text{ mg/m}^3$			
Reaction mass of ethylbenzene and xyleneDNELLong term Oral1.6 mg/kg bw/dayGeneral populationSyst populationDNELLong term Inhalation14.8 mg/m³General populationSyst populationDNELLong term Inhalation77 mg/m³WorkersSyst populationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal180 mg/kg bw/dayWorkersSyst populationA-methylpentan-2-oneDNELShort term Inhalation289 mg/m³ bw/dayWorkersSyst population4-methylpentan-2-oneDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSyst populationDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSyst populationDNELLong term Dermal11.8 mg/ kg bw/daySyst populationSyst populationDNELLong term Dermal11.8 mg/ kg bw/daySyst populationSyst populationDNELLong term Dermal14.7 mg/m³ g bw/dayGeneral populationSyst populationDNELLong term Dermal14.7 mg/m³ g bw/dayGeneral populationSyst populationDNELLong term Dermal14.7 mg/m³ g bw/dayGeneral population <td>ysternic</td> <td>WUIKEIS</td> <td>900 mg/m</td> <td></td> <td>DINEL</td> <td></td>	ysternic	WUIKEIS	900 mg/m		DINEL	
xylenebw/day Inhalationpopulation General populationDNELLong term Inhalation14.8 mg/m³General populationDNELLong term Inhalation77 mg/m³WorkersSystONELLong term Dermal108 mg/kg bw/dayGeneral populationSystDNELLong term Dermal108 mg/kg bw/dayWorkersSystDNELLong term Dermal180 mg/kg bw/dayWorkersSystDNELShort term Inhalation289 mg/m³WorkersLocaDNELShort term Inhalation289 mg/m³WorkersSystDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystONELLong term Dermal11.8 mg/ kg bw/daySystDNELLong term Dermal11.8 mg/ kg bw/daySystDNELLong term Dermal14.7 mg/m³General populationSystDNELLong term Dermal14.7 mg/m³General populationSyst	votomio	Conorol	1.6 mg/kg			Departies many of other departments on
A-methylpentan-2-oneDNELLong term Inhalation DNEL14.8 mg/m³General population WorkersSyst4-methylpentan-2-oneDNELLong term Dermal108 mg/kg bw/dayGeneral populationSyst4-methylpentan-2-oneDNELLong term Dermal180 mg/kg bw/dayWorkersSystDNELLong term Dermal180 mg/kg bw/dayWorkersSystDNELShort term Inhalation DNEL289 mg/m³ bw/dayWorkersSystDNELShort term Inhalation DNEL289 mg/m³ bw/dayWorkersSystDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystDNELLong term Dermal11.8 mg/ kg bw/daySystDNELLong term Dermal11.8 mg/ kg bw/daySystDNELLong term Dermal14.7 mg/m³General populationSystDNELLong term Dermal11.8 mg/ kg bw/daySystDNELLong term Inhalation14.7 mg/m³General populationSyst	ysternic			Long term Oral		
Inhalation Long term Inhalationpopulation WorkersSystDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystDNELLong term Dermal108 mg/kg bw/dayWorkersSystDNELLong term Dermal180 mg/kg bw/dayWorkersSystDNELShort term Inhalation289 mg/m³WorkersSystDNELShort term Inhalation289 mg/m³WorkersSystONELShort term Inhalation289 mg/m³WorkersSystDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSystDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSystDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSystDNELLong term Dermal11.7 mg/m³General populationSystDNELLong term14.7 mg/m³General populationLoca				1		xylene
DNELLong term Inhalation77 mg/m³WorkersSystDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystDNELLong term Dermal180 mg/kg bw/dayWorkersSystDNELShort term Inhalation289 mg/m³WorkersSyst0NELShort term Inhalation289 mg/m³WorkersSyst0NELShort term Inhalation289 mg/m³WorkersSyst0NELShort term Inhalation289 mg/m³WorkersSyst0NELLong term Oral4.2 mg/kg bw/dayGeneral populationSyst0NELLong term Dermal4.2 mg/kg bw/dayGeneral populationSyst0NELLong term Dermal11.8 mg/ kg bw/dayWorkersSyst0NELLong term Dermal14.7 mg/m³General populationLoca	systemic		14.8 mg/m <sup>s</sup>		DNEL	
InhalationInhalationInhalationDNELLong term Dermal108 mg/kg bw/dayGeneral populationSystDNELLong term Dermal180 mg/kg bw/dayWorkersSystDNELShort term Inhalation289 mg/m³WorkersLoca0NELShort term Inhalation289 mg/m³WorkersSyst0NELShort term Inhalation289 mg/m³WorkersSyst0NELLong term Oral4.2 mg/kg bw/dayGeneral populationSyst0NELLong term Dermal4.2 mg/kg bw/dayGeneral populationSyst0NELLong term Dermal11.8 mg/ kg bw/daySyst0NELLong term Dermal11.7 mg/m³General populationSyst0NELLong term Inhalation14.7 mg/m³General populationLoca			77			
DNELLong term Dermal108 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal180 mg/kg bw/dayWorkersSyst populationDNELShort term Inhalation289 mg/m³WorkersLoca syst population4-methylpentan-2-oneDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSyst populationDNELLong term Oral4.2 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSyst populationDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSyst populationDNELLong term Dermal11.7 mg/m³General populationLoca populationDNELLong term14.7 mg/m³General populationLoca population	systemic	workers	// mg/m <sup>s</sup>		DNEL	
4-methylpentan-2-one DNEL Long term Dermal bw/day population DNEL Short term 289 mg/m³ Workers Loca Inhalation DNEL Short term 289 mg/m³ Workers Syst Inhalation DNEL Long term Oral 4.2 mg/kg General Syst bw/day population DNEL Long term Dermal 4.2 mg/kg General Syst bw/day population DNEL Long term Dermal 11.8 mg/ kg bw/day DNEL Long term 14.7 mg/m³ General Loca			400 "			
DNELLong term Dermal180 mg/kg bw/dayWorkersSystbw/dayDNELShort term289 mg/m³WorkersLocaInhalationDNELShort term289 mg/m³WorkersSystInhalationDNELShort term289 mg/m³WorkersSystInhalationDNELLong term Oral4.2 mg/kgGeneralSystInhalationDNELLong term Dermal4.2 mg/kgGeneralSystDNELLong term Dermal4.2 mg/kgGeneralSystDNELLong term Dermal11.8 mg/WorkersSystDNELLong term Dermal11.8 mg/WorkersSystDNELLong term14.7 mg/m³GeneralLocaDNELLong term14.7 mg/m³GeneralLoca	systemic			Long term Dermal	DNEL	
4-methylpentan-2-one DNEL Short term linhalation DNEL Short term 289 mg/m <sup>3</sup> Workers Syst Inhalation DNEL Long term Oral 4.2 mg/kg General Syst bw/day population DNEL Long term Dermal 4.2 mg/kg General Syst bw/day population DNEL Long term Dermal 11.8 mg/ bw/day DNEL Long term Dermal 11.8 mg/ bw/day BONEL Long term Dermal 11.8 mg/ bw/day BONEL Long term Dermal 14.7 mg/m <sup>3</sup> General Loca						
A-methylpentan-2-oneDNELShort term Inhalation289 mg/m³WorkersLoca4-methylpentan-2-oneDNELShort term Inhalation289 mg/m³WorkersSystDNELLong term Oral4.2 mg/kgGeneral populationSystDNELLong term Dermal4.2 mg/kgGeneral populationSystDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSystDNELLong term Dermal11.8 mg/ kg bw/daySystDNELLong term Dermal14.7 mg/m³General populationLoca	systemic	Workers		Long term Dermal	DNEL	
4-methylpentan-2-one DNEL Short term 289 mg/m³ Workers Syst Inhalation DNEL Long term Oral 4.2 mg/kg General Syst bw/day population DNEL Long term Dermal 4.2 mg/kg General Syst bw/day population DNEL Long term Dermal 11.8 mg/ Workers Syst kg bw/day DNEL Long term 14.7 mg/m³ General Loca						
4-methylpentan-2-one DNEL Short term lnhalation DNEL Long term Oral 4.2 mg/kg General Syst bw/day population DNEL Long term Dermal 4.2 mg/kg General Syst bw/day population DNEL Long term Dermal 11.8 mg/ DNEL Long term Dermal 11.8 mg/ Workers Syst kg bw/day DNEL Long term 14.7 mg/m³ General Loca	ocal	Workers	289 mg/m³		DNEL	
4-methylpentan-2-one DNEL Long term Oral 4.2 mg/kg General Syst bw/day population DNEL Long term Dermal 4.2 mg/kg General Syst bw/day population DNEL Long term Dermal 11.8 mg/ kg bw/day DNEL Long term 14.7 mg/m³ General Loca population						
4-methylpentan-2-one DNEL Long term Oral 4.2 mg/kg General Syst bw/day population Syst bw/day population Syst bw/day population Syst bw/day population Syst bw/day population Syst bw/day population Long term Dermal 11.8 mg/ kg bw/day DNEL Long term 14.7 mg/m³ General Loca population Syst	systemic	Workers	289 mg/m³		DNEL	
DNEL     Long term Dermal     bw/day     population       DNEL     Long term Dermal     4.2 mg/kg     General     Syst       bw/day     population     11.8 mg/     Workers     Syst       DNEL     Long term Dermal     11.7 mg/m³     General     Syst       DNEL     Long term     14.7 mg/m³     General     Loca       Inhalation     population     Dot     Dot						
DNELLong term Dermal4.2 mg/kg bw/dayGeneral populationSyst Syst SystDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSyst Syst SystDNELLong term Inhalation14.7 mg/m³ opulationGeneral populationLoca population	systemic			Long term Oral	DNEL	4-methylpentan-2-one
DNELLong term Dermalbw/daypopulationDNELLong term Dermal11.8 mg/ kg bw/dayWorkersSystDNELLong term Inhalation14.7 mg/m³General populationLoca						
DNELLong term Dermal11.8 mg/ kg bw/dayWorkersSystDNELLong term14.7 mg/m³GeneralLocaInhalationInhalationInhalationLoca	systemic			Long term Dermal	DNEL	
DNEL Long term 14.7 mg/m³ General Loca Inhalation population						
DNEL Long term 14.7 mg/m³ General Loca Inhalation population	systemic	Workers		Long term Dermal	DNEL	
Inhalation population						
Inhalation population	ocal	General	14.7 mg/m <sup>3</sup>	Long term	DNEL	
			-			
	systemic		14.7 mg/m³	Long term	DNEL	
			-	-		
e of issue/Date of revision : 1-10-2022 Version : 1		:1	Version		10-2022	e of issue/Date of revision : 1-1
	AkzoNob			lidation		

ECTION 8: Exposure controls/personal protection						
		Inhalation		population		
	DNEL	Long term	83 mg/m³	Workers	Local	
		Inhalation				
	DNEL	Long term	83 mg/m³	Workers	Systemic	
		Inhalation				
	DNEL	Short term	155.2 mg/	General	Local	
	_	Inhalation	m³	population		
	DNEL	Short term	155.2 mg/	General	Systemic	
		Inhalation	m <sup>3</sup>	population		
	DNEL	Short term	208 mg/m <sup>3</sup>	Workers	Local	
		Inhalation				
	DNEL	Short term	208 mg/m <sup>3</sup>	Workers	Systemic	
		Inhalation	0.405	O a m a mal	Quanta maila	
butan-1-ol	DNEL	Long term Oral	3.125 mg/	General	Systemic	
		Long torm	kg bw/day	population		
	DNEL	Long term Inhalation	55 mg/m³	General population	Local	
	DNEL	Long term	310 mg/m <sup>3</sup>	Workers	Local	
	DINLL	Inhalation	5 to mg/m	WUIKEIS	LUCAI	
4-morpholinecarbaldehyde	DNEL	Long term Oral	8 mg/kg	General	Systemic	
	DINCE	Long term Oran	bw/day	population	Oysternie	
	DNEL	Long term Dermal	8 mg/kg	General	Systemic	
	DITE	Long tonin Donnai	bw/day	population	Cyclonno	
	DNEL	Long term Dermal	14 mg/kg	Workers	Systemic	
			bw/day		- ,	
	DNEL	Long term	29 mg/m <sup>3</sup>	General	Systemic	
		Inhalation	Ŭ	population		
	DNEL	Long term	98 mg/m³	Workers	Systemic	
		Inhalation			-	

### **PNECs**

No PNECs available.

8.2 Exposure controls					
Appropriate engineering : controls	Use only with adequate ventilation. Use process enclosures, local exhaust ventilation or other engineering controls to keep worker exposure to airborne contaminants below any recommended or statutory limits. The engineering controls also need to keep gas, vapor or dust concentrations below any lower explosive limits. Use explosion-proof ventilation equipment.				
Individual protection measure	<u>IS</u>				
Hygiene measures	: Wash hands, forearms and face thoroughly after handling chemical products, before eating, smoking and using the lavatory and at the end of the working per Appropriate techniques should be used to remove potentially contaminated clock Wash contaminated clothing before reusing. Ensure that eyewash stations an safety showers are close to the workstation location.				
Eye/face protection	Safety eyewear complying with an approved standard should be used when a risk assessment indicates this is necessary to avoid exposure to liquid splashes, mists, gases or dusts. If contact is possible, the following protection should be worn, unless the assessment indicates a higher degree of protection: chemical splash goggles.				
Skin protection					
Hand protection	: Chemical-resistant, impervious gloves complying with an approved standard sho be worn at all times when handling chemical products if a risk assessment indica this is necessary. Considering the parameters specified by the glove manufactur check during use that the gloves are still retaining their protective properties. It should be noted that the time to breakthrough for any glove material may be different for different glove manufacturers. In the case of mixtures, consisting of several substances, the protection time of the gloves cannot be accurately estimated.				
Date of issue/Date of revision	: 1-10-2022	Version :1			
Date of previous issue	: No previous validation	9/19	AkzoNobel		

# **SECTION 8: Exposure controls/personal protection**

•	
	When prolonged or frequently repeated contact may occur, a glove with a protection class of 6 (breakthrough time >480 minutes according to EN374) is recommended. Recommended gloves: Viton ® or Nitrile, thickness $\geq$ 0.38 mm. When only brief contact is expected, a glove with protection class of 2 or higher (breakthrough time >30 minutes according to EN374) is recommended. Recommended gloves: Nitrile, thickness $\geq$ 0.12 mm. Gloves should be replaced regularly and if there is any sign of damage to the glove material.
	The performance or effectiveness of the glove may be reduced by physical/ chemical damage and poor maintenance.
	The user must check that the final choice of type of glove selected for handling this product is the most appropriate and takes into account the particular conditions of use, as included in the user's risk assessment.
Body protection	: Personal protective equipment for the body should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product. When there is a risk of ignition from static electricity, wear anti-static protective clothing. For the greatest protection from static discharges, clothing should include anti-static overalls, boots and gloves. Refer to European Standard EN 1149 for further information on material and design requirements and test methods.
Other skin protection	: Appropriate footwear and any additional skin protection measures should be selected based on the task being performed and the risks involved and should be approved by a specialist before handling this product.
Respiratory protection	: Based on the hazard and potential for exposure, select a respirator that meets the appropriate standard or certification. Respirators must be used according to a respiratory protection program to ensure proper fitting, training, and other important aspects of use.
Environmental exposure controls	: Emissions from ventilation or work process equipment should be checked to ensure they comply with the requirements of environmental protection legislation. In some cases, fume scrubbers, filters or engineering modifications to the process equipment will be necessary to reduce emissions to acceptable levels.

# **SECTION 9: Physical and chemical properties**

### 9.1 Information on basic physical and chemical properties

<u>Appearance</u>			
Physical state	: Liquid.		
Color	: Silver.		
Odor	: Characteristic.		
Odor threshold	: Not available.		
рН	Not available.		
Melting point/freezing point	: Not available.		
Initial boiling point and boiling range	: Not available.		
Flash point	: Closed cup: 24°C		
Evaporation rate	: Not available.		
Flammability (solid, gas)	: Not available.		
Upper/lower flammability or explosive limits	: Not available.		
Vapor pressure	: Not available.		
Vapor density	: Highest known value: 4.5 Weighted average: 2.81	(Air = 1) (Solvent naphtha ( (Air = 1)	petroleum), light arom.).
Density	: 1.062 g/cm <sup>3</sup>		
Solubility(ies)	: Insoluble in the following r	naterials: cold water.	
Date of issue/Date of revision	: 1-10-2022	Version :1	
Date of previous issue	: No previous validation	10/19	AkzoNobel

# SECTION 9: Physical and chemical properties

Partition coefficient: n-octanol/ water	:	Not available.
Auto-ignition temperature	:	Not available.
Decomposition temperature	:	Not available.
Viscosity	:	Kinematic (room temperature): 10.36 cm²/s Kinematic (40°C): 2.01 cm²/s

SECTION 10: Stability and reactivity					
10.1 Reactivity	: No specific test data related to reactivity available for this product or its ingredients.				
10.2 Chemical stability	: The product is stable.				
10.3 Possibility of hazardous reactions	: Under normal conditions of storage and use, hazardous reactions will not occur.				
10.4 Conditions to avoid	: Avoid all possible sources of ignition (spark or flame). Do not pressurize, cut, weld, braze, solder, drill, grind or expose containers to heat or sources of ignition.				
10.5 Incompatible materials	: Reactive or incompatible with the following materials: oxidizing materials				
10.6 Hazardous decomposition products	: Under normal conditions of storage and use, hazardous decomposition products should not be produced.				

# **SECTION 11: Toxicological information**

### 11.1 Information on toxicological effects

### Acute toxicity

Product/ingredient name	Result	Species	Dose	Exposure
n-butyl acetate	LC50 Inhalation Gas.	Rat	390 ppm	4 hours
-	LC50 Inhalation Vapor	Mouse	6 g/m <sup>3</sup>	2 hours
	LD50 Dermal	Rabbit	>17600 mg/kg	-
	LD50 Intraperitoneal	Mouse	1230 mg/kg	-
	LD50 Oral	Guinea pig	4700 mg/kg	-
	LD50 Oral	Mouse	6 g/kg	-
	LD50 Oral	Rabbit	3200 mg/kg	-
	LD50 Oral	Rat	10768 mg/kg	-
Reaction mass of ethylbenzene and xylene	LC50 Inhalation Gas.	Rat	5000 ppm	4 hours
4-methylpentan-2-one	LD50 Intraperitoneal	Guinea pig	800 mg/kg	-
	LD50 Intraperitoneal	Mouse	268 mg/kg	-
	LD50 Intraperitoneal	Rat	400 mg/kg	-
	LD50 Oral	Guinea pig	1600 mg/kg	-
	LD50 Oral	Mouse	1900 mg/kg	-
	LD50 Oral	Mouse	2850 mg/kg	-
	LD50 Oral	Rat	2080 mg/kg	-
	LD50 Oral	Rat	4600 mg/kg	-
Naphtha (petroleum), hydrotreated heavy	LC50 Inhalation Vapor	Rat	8500 mg/m <sup>3</sup>	4 hours
	LD50 Oral	Rat	>6 g/kg	-
Solvent naphtha (petroleum), light arom.	LD50 Oral	Rat	8400 mg/kg	-
butan-1-ol	LC50 Inhalation Vapor	Rat	24000 mg/m <sup>3</sup>	4 hours
	LD50 Dermal	Rabbit	3400 mg/kg	-
	LD50 Intraperitoneal	Mouse	254 mg/kg	-
e of issue/Date of revision	: 1-10-2022	Version	n :1	
e of previous issue	: No previous validation	11/19		AkzoNob

# **SECTION 11: Toxicological information**

	LD50 Intraperitoneal	Rat	200 mg/kg	-			
	LD50 Intravenous	Mouse	377 mg/kg	-			
	LD50 Intravenous	Rat	310 mg/kg	-			
	LD50 Oral	Mouse	100 mg/kg	-			
	LD50 Oral	Rabbit	3484 mg/kg	-			
	LD50 Oral	Rabbit	3400 mg/kg	-			
	LD50 Oral	Rat	0.79 g/kg	-			
	LD50 Oral	Rat	4.36 g/kg	-			
	LD50 Oral	Rat	790 mg/kg	-			
	LD50 Subcutaneous	Mouse	3200 mg/kg	-			
4-morpholinecarbaldehyde	LD50 Oral	Rat	6500 uL/kg	-			

**Conclusion/Summary** : Not available.

### Irritation/Corrosion

Product/ingredient name	Result	Species	Score	Exposure	Observation
n-butyl acetate	Eyes - Moderate irritant	Rabbit	-	100 mg	-
-	Skin - Moderate irritant	Rabbit	-	24 hours 500	-
				mg	
Reaction mass of ethylbenzene and xylene	Eyes - Mild irritant	Rabbit	-	87 mg	-
, , , , , , , , , , , , , , , , , , ,	Eyes - Severe irritant	Rabbit	-	24 hours 5 mg	-
	Skin - Mild irritant	Rat	_	8 hours 60 UI	_
	Skin - Moderate irritant	Rabbit	_	24 hours 500	-
				mg	
	Skin - Moderate irritant	Rabbit	-	100 %	-
4-methylpentan-2-one	Eyes - Moderate irritant	Rabbit	-	24 hours 100	-
	-			UI	
	Eyes - Severe irritant	Rabbit	-	40 mg	-
	Skin - Mild irritant	Rabbit	-	24 hours 500	-
				mg	
Solvent naphtha (petroleum), light arom.	Eyes - Mild irritant	Rabbit	-	24 hours 100 Ul	-
butan-1-ol	Eyes - Severe irritant	Rabbit	-	24 hours 2	-
				mg	
	Eyes - Severe irritant	Rabbit	-	0.005 MI	-
	Eyes - Severe irritant	Rabbit	-	1.62 mg	-
	Skin - Moderate irritant	Rabbit	-	24 hours 20	-
		<b>D</b> 11 11		mg	
4-morpholinecarbaldehyde	Eyes - Mild irritant	Rabbit	-	24 hours 500	-
	Skin - Mild irritant	Pobbit		mg 24 hours 500	
		Rabbit	-		-
				mg	
Conclusion/Summary	: Not available.				
Sensitization					

Sensilization		
<b>Conclusion/Summary</b>	:	Not available.
<u>Mutagenicity</u>		
<b>Conclusion/Summary</b>	:	Not available.
<b>Carcinogenicity</b>		
<b>Conclusion/Summary</b>	:	Not available.
Reproductive toxicity		
<b>Conclusion/Summary</b>	:	Not available.
<u>Teratogenicity</u>		
<b>Conclusion/Summary</b>	:	Not available.
Specific target organ toxicity	/ (:	<u>single exposure)</u>



# **SECTION 11: Toxicological information**

Product/ingredient name	Category	Route of exposure	Target organs
n-butyl acetate	Category 3	-	Narcotic effects
Reaction mass of ethylbenzene and xylene	Category 3	-	Respiratory tract irritation
4-methylpentan-2-one	Category 3	-	Narcotic effects
Naphtha (petroleum), hydrotreated heavy	Category 3	-	Narcotic effects
Solvent näphtha (petroleum), light arom.	Category 3	-	Respiratory tract irritation
	Category 3		Narcotic effects
butan-1-ol	Category 3	-	Respiratory tract irritation
	Category 3		Narcotic effects

### Specific target organ toxicity (repeated exposure)

Product/ingredient name	Category	Route of exposure	Target organs
Reaction mass of ethylbenzene and xylene	Category 2	-	-

### Aspiration hazard

Product/ingredient name	Result
Reaction mass of ethylbenzene and xylene	ASPIRATION HAZARD - Category 1
Naphtha (petroleum), hydrotreated heavy	ASPIRATION HAZARD - Category 1
Solvent naphtha (petroleum), light arom.	ASPIRATION HAZARD - Category 1

### Information on the likely : Not available.

### routes of e

routes of exposure	
Potential acute health offects	

<u>nealth effect</u>	acute	Potential
----------------------	-------	-----------

Eye contact	: Causes serious eye irritation.
Inhalation	: Can cause central nervous system (CNS) depression. May cause drowsiness or dizziness.
Skin contact	: Causes skin irritation.
Ingestion	: Can cause central nervous system (CNS) depression.

### Symptoms related to the physical, chemical and toxicological characteristics

Eye contact	: Adverse symptoms may include the following: pain or irritation watering redness
Inhalation	: Adverse symptoms may include the following: nausea or vomiting headache drowsiness/fatigue dizziness/vertigo unconsciousness
Skin contact	: Adverse symptoms may include the following: irritation redness
Ingestion	: No specific data.

# Delayed and immediate effects and also chronic effects from short and long term exposure

<u>Short term exposure</u>
Potential immediate
effects

: Not available.

Date of issue/Date of revision Date of previous issue

: 1-10-2022 : No previous validation



# **SECTION 11: Toxicological information**

	•
Potential delayed effects	: Not available.
Long term exposure	
Potential immediate effects	: Not available.
Potential delayed effects	: Not available.
Potential chronic health eff	ects
Not available.	
Conclusion/Summary	: Not available.
General	: May cause damage to organs through prolonged or repeated exposure.
Carcinogenicity	: Suspected of causing cancer. Risk of cancer depends on duration and level of exposure.
Mutagenicity	: No known significant effects or critical hazards.
Reproductive toxicity	: No known significant effects or critical hazards.
Other information	: Not available.

# **SECTION 12: Ecological information**

### 12.1 Toxicity

There are no data available on the mixture itself. Do not allow to enter drains or watercourses.

The mixture has been assessed following the summation method of the CLP Regulation (EC) No 1272/2008 and is
classified for eco-toxicological properties accordingly. See Sections 2 and 3 for details.

Product/ingredient name	Result	Species	Exposure
n-butyl acetate	Acute LC50 32 mg/l Marine water	Crustaceans - Artemia salina	48 hours
	Acute LC50 100000 µg/l Fresh water	Fish - Lepomis macrochirus	96 hours
	Acute LC50 18000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 185000 µg/l Marine water	Fish - Menidia beryllina	96 hours
	Acute LC50 62000 µg/l Fresh water	Fish - Danio rerio	96 hours
Reaction mass of ethylbenzene and xylene	Acute LC50 13400 µg/l Fresh water	Fish - Pimephales promelas	96 hours
4-methylpentan-2-one	Acute LC50 505000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 540000 µg/l Fresh water	Fish - Pimephales promelas	96 hours
	Acute LC50 537000 µg/l Fresh water	Fish - Pimephales promelas - Juvenile (Fledgling, Hatchling, Weanling)	96 hours
	Chronic NOEC 78 mg/l Fresh water	Daphnia - Daphnia magna	21 days
	Chronic NOEC 168 mg/l Fresh water	Fish - Pimephales promelas - Embryo	33 days
butan-1-ol	Acute EC50 1983 mg/l Fresh water	Daphnia - Daphnia magna	48 hours
	Acute LC50 2300000 µg/l Marine water	Fish - Alburnus alburnus	96 hours
	Acute LC50 1910000 µg/l Fresh water	Fish - Pimephales promelas - Juvenile (Fledgling, Hatchling, Weanling)	96 hours
	Acute LC50 1940000 μg/l Fresh water	Fish - Pimephales promelas - Juvenile (Fledgling, Hatchling, Weanling)	96 hours
	Acute LC50 1730000 µg/l Fresh water	Fish - Pimephales promelas	96 hours

### 12.2 Persistence and degradability

**Conclusion/Summary** : Not available.



# **SECTION 12: Ecological information**

### 12.3 Bioaccumulative potential

Product/ingredient name	LogPow	BCF	Potential
n-butyl acetate	2.3	-	low
Reaction mass of	3.12	8.1 to 25.9	low
ethylbenzene and xylene	1.0		law
4-methylpentan-2-one	1.9	- 10 to 2500	low
Naphtha (petroleum), hydrotreated heavy	-	10 to 2500	high
Solvent naphtha (petroleum),	-	10 to 2500	high
light arom.			
butan-1-ol	1	-	low
4-morpholinecarbaldehyde	-	<1.9	low

### 12.4 Mobility in soil

Soil/water partition coefficient (K <sub>oc</sub> )	: Not available.
Mobility	: Not available.

### 12.5 Results of PBT and vPvB assessment

This mixture does not contain any substances that are assessed to be a PBT or a vPvB.

### **12.6 Other adverse effects** : No known significant effects or critical hazards.

# **SECTION 13: Disposal considerations**

The information in this section contains generic advice and guidance. The list of Identified Uses in Section 1 should be consulted for any available use-specific information provided in the Exposure Scenario(s).

### 13.1 Waste treatment methods

<u>Product</u>	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Disposal of this product, solutions and any by-products should at all times comply with the requirements of environmental protection and waste disposal legislation and any regional local authority requirements. Dispose of surplus and non- recyclable products via a licensed waste disposal contractor. Waste should not be disposed of untreated to the sewer unless fully compliant with the requirements of all authorities with jurisdiction.
Hazardous waste	: The classification of the product may meet the criteria for a hazardous waste.
Disposal considerations	<ul> <li>Do not allow to enter drains or watercourses.</li> <li>Dispose of according to all federal, state and local applicable regulations.</li> <li>If this product is mixed with other wastes, the original waste product code may no longer apply and the appropriate code should be assigned.</li> <li>For further information, contact your local waste authority.</li> </ul>

### European waste catalogue (EWC)

The European Waste Catalogue classification of this product, when disposed of as waste, is:

when recycling is not feasible.

Waste code	Waste designation
EWC 08 01 11*	waste paint and varnish containing organic solvents or other hazardous substances
Packaging	
Methods of disposal	: The generation of waste should be avoided or minimized wherever possible. Waste packaging should be recycled. Incineration or landfill should only be considered



## **SECTION 13: Disposal considerations**

Disposal considerations	<ul> <li>Using information provided in this safety data sheet, advice should be obtained from the relevant waste authority on the classification of empty containers. Empty containers must be scrapped or reconditioned. Dispose of containers contaminated by the product in accordance with local or national legal provisions.</li> </ul>
Special precautions	: This material and its container must be disposed of in a safe way. Care should be taken when handling emptied containers that have not been cleaned or rinsed out. Empty containers or liners may retain some product residues. Vapor from product residues may create a highly flammable or explosive atmosphere inside the container. Do not cut, weld or grind used containers unless they have been cleaned thoroughly internally. Avoid dispersal of spilled material and runoff and contact with soil, waterways, drains and sewers.

# **SECTION 14: Transport information**

	ADR/RID	IMDG	IATA
14.1 UN number	UN1263	UN1263	UN1263
14.2 UN proper shipping name	PAINT	PAINT	PAINT
14.3 Transport hazard class(es)	3	3	3
14.4 Packing group	111	111	111
14.5 Environmental hazards	No.	No.	No.

Additional information

ADR/RID	:	<u>Viscous liquid exception</u> This class 3 viscous liquid is not subject to regulation in packagings up to 450 L according to 2.2.3.1.5.1. <u>Tunnel code</u> (D/E)
IMDG	:	<b>Emergency schedules</b> F-E, _S-E_ <b>Viscous liquid exception</b> This class 3 viscous liquid is not subject to regulation in packagings up to 450 L according to 2.3.2.5.
14.6 Special precautions for user	:	<b>Transport within user's premises:</b> always transport in closed containers that are upright and secure. Ensure that persons transporting the product know what to do in the event of an accident or spillage.
14.7 Transport in bulk according to IMO instruments	:	Not applicable.

# **SECTION 15: Regulatory information**

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

### EU Regulation (EC) No. 1907/2006 (REACH)

#### Annex XIV - List of substances subject to authorization

#### Annex XIV

None of the components are listed.

### Substances of very high concern

Date of issue/Date of revision Date of previous issue



# **SECTION 15: Regulatory information**

None of the components are listed.

Annex XVII - Restrictions : Not applicable. on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles

### **Other EU regulations**

VOC

: The provisions of Directive 2004/42/EC on VOC apply to this product. Refer to the product label and/or technical data sheet for further information.

### **VOC for Ready-for-Use** : Not applicable.

Mixture		
Industrial emissions (integrated pollution prevention and control) - Air	:	Listed
Industrial emissions (integrated pollution prevention and control) - Water	:	Not listed

### Ozone depleting substances (1005/2009/EU)

Not listed.

### Prior Informed Consent (PIC) (649/2012/EU)

Not listed.

### Seveso Directive

This product is controlled under the Seveso Directive.

### Danger criteria

Category			
P5c			
National regulations			
Industrial use	: The information contained in t own assessment of workplace legislation. The provisions of t to the use of this product at wo	e risks, as required by other he he national health and safety a	ealth and safety
VOC content	: VOC (w/w): 50%		
International regulations			
Chemical Weapon Conve	ntion List Schedules I, II & III Cher	<u>nicals</u>	
Not listed.			
Montreal Protocol			
Not listed.			
Stockholm Convention or Not listed.	<u>n Persistent Organic Pollutants</u>		
Rotterdam Convention or Not listed.	<u>n Prior Informed Consent (PIC)</u>		
UNECE Aarhus Protocol o	on POPs and Heavy Metals		
Not listed.			
Inventory list			
Europe	: Not determined.		
ate of issue/Date of revision	: 1-10-2022	Version : 1	
ate of previous issue	: No previous validation	17/19	AkzoNobe

# **SECTION 15: Regulatory information**

**15.2 Chemical Safety** : No Chemical Safety Assessment has been carried out. **Assessment** 

# **SECTION 16: Other information**

Indicates information that has changed from previously issued version.

Abbreviations and acronyms	<ul> <li>ATE = Acute Toxicity Estimate CLP = Classification, Labelling and Packaging Regulation [Regulation (EC) No. 1272/2008] DMEL = Derived Minimal Effect Level DNEL = Derived No Effect Level EUH statement = CLP-specific Hazard statement N/A = Not available PBT = Persistent, Bioaccumulative and Toxic PNEC = Predicted No Effect Concentration RRN = REACH Registration Number SGG = Segregation Group vPvB = Very Persistent and Very Bioaccumulative</li> </ul>
	vPvB = Very Persistent and Very Bioaccumulative

### Procedure used to derive the classification according to Regulation (EC) No. 1272/2008 [CLP/GHS]

Classification	Justification
Flam. Liq. 3, H226	On basis of test data
Skin Irrit. 2, H315	Calculation method
Eye Irrit. 2, H319	Calculation method
Carc. 2, H351	Calculation method
STOT SE 3, H336	Calculation method
STOT RE 2, H373	Calculation method
Aquatic Chronic 3, H412	Calculation method

### Full text of abbreviated H statements

H225	Highly flammable liquid and vapor.
H226	Flammable liquid and vapor.
H302	Harmful if swallowed.
H304	May be fatal if swallowed and enters airways.
H312	Harmful in contact with skin.
H315	Causes skin irritation.
H317	May cause an allergic skin reaction.
H318	Causes serious eye damage.
H319	Causes serious eye irritation.
H332	Harmful if inhaled.
H335	May cause respiratory irritation.
H336	May cause drowsiness or dizziness.
H351	Suspected of causing cancer.
H373	May cause damage to organs through prolonged or repeated
	exposure.
H411	Toxic to aquatic life with long lasting effects.
H412	Harmful to aquatic life with long lasting effects.
EUH066	Repeated exposure may cause skin dryness or cracking.

### Full text of classifications [CLP/GHS]

Acute Tox. 4		ACUTE TOXICITY - Category 4
Aquatic Chronic 2		AQUATIC HAZARD (LONG-TERM) - Category 2
Aquatic Chronic 3		AQUATIC HAZARD (LONG-TERM) - Category 3
Asp. Tox. 1		ASPIRATION HAZARD - Category 1
Carc. 2		CARCINOGENICITY - Category 2
Eye Dam. 1		SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 1
Eye Irrit. 2		SERIOUS EYE DAMAGE/ EYE IRRITATION - Category 2
Flam. Liq. 2		FLAMMABLE LIQUIDS - Category 2
Flam. Liq. 3		FLAMMABLE LIQUIDS - Category 3
Skin Irrit. 2		SKIN CORROSION/IRRITATION - Category 2
Date of issue/Date of revision	: 1-10-2022	Version :1

Date of previous issue

: No previous validation

18/19



SECTION 16: Other information			
Skin Sens. 1		SKIN SENSITIZATION - Category 1	
STOT RE 2		SPECIFIC TARGET ORGAN TOXICITY (REPEATED EXPOSURE) - Category 2	
STOT SE 3		SPECIFIC TÁRGET ORGAN TOXICITY (SINGLE EXPOSURE) - Category 3	
Date of printing	: 1 October 2022		
Date of issue/ Date of revision	: 1 October 2022		
Date of previous issue	: No previous validation		
Version	: 1		
Unique ID	:		

### Notice to reader

FOR PROFESSIONAL USE ONLY

IMPORTANT NOTE The information in this data sheet is not intended to be exhaustive and is based on the present state of our knowledge and on current laws: any person using the product for any purpose other than that specifically recommended in the technical data sheet without first obtaining written confirmation from us as to the suitability of the product for the intended purpose does so at his own risk. It is always the responsibility of the user to take all necessary steps to fulfill the demands set out in the local rules and legislation. Always read the Material Data Sheet and the Technical Data Sheet for this product if available. All advice we give or any statement made about the product by us (whether in this data sheet or otherwise) is correct to the best of our knowledge but we have no control over the quality or the condition of the substrate or the many factors affecting the use and application of the product. Therefore, unless we specifically agree in writing otherwise, we do not accept any liability whatsoever for the performance of the product or for any loss or damage arising out of the use of the product. All products supplied and technical advice given are subject to our standard terms and conditions of sale. You should request a copy of this document and review it carefully. The information contained in this data sheet is subject to modification from time to time in the light of experience and our policy of continuous development. It is the user's responsibility to verify that this data sheet is current prior to using the product.

Brand names mentioned in this data sheet are trademarks of or are licensed to Akzo Nobel.

